Skip to content
Screener

Krystal Biotech, Inc. KRYS Total Liabilities & Equity

Total Liabilities & Equity at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.26B-3.2%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$1.37B+55.5%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$1.1B+88.4%
Regenxbio logo
RegenxbioRGNX
$386.62M-33.5%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$302.71M+18.1%

Other financials

Income statement

See full
Revenue$116.4M+31.9%
Operating income$53.7M+48.1%
Net income$55.9M+56.5%
EPS (diluted)$1.83+52.5%

Balance sheet

See full
Cash & equivalents$501.3M+62.4%
Total debt$9.1M-5.7%
Total equity$1.3B+29.7%
Total assets$1.4B+30.0%

Cash flow

See full
Operating cash flow$80.4M+160%
CapEx$7.1M+15.2%
Free cash flow$73.2M+196%

Valuation

See full
Market cap$9.64B+145%
Enterprise value$9.15B+155%
P/E42.9×+16.0×
P/S23.1×+12.2×

Profitability

See full
Operating margin42.8%+10.2pp
Net margin53.9%+16.7pp
FCF margin56.9%+16.5pp

Returns & leverage

See full
Return on equity19.9%+6.0pp
Debt / equity0.0×
Current ratio9.5×-0.2×

Where this comes from

Reported directly by Krystal Biotech, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026.

Filed
May 4, 2026, 7:06 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001711279-26-000043
(in thousands, except par value)March 31,2026December 31,2025
Commitments and contingencies (see note 7)
Stockholders’ equity
Common stock; $0.00001 par value; 80,000 shares authorized as of March 31, 2026 and December 31, 2025; 29,437 and 29,192 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively.
Additional paid-in capital1,198,2571,194,261
Accumulated other comprehensive (loss) gain(1,623)1,136
Retained earnings80,09524,163
Total stockholders’ equity1,276,7291,219,560
Total liabilities and stockholders’ equity$1,396,967$1,333,794

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Krystal Biotech, Inc.'s total liabilities & equity?
Krystal Biotech, Inc. (KRYS) reported total liabilities & equity of $1.4B in Q1 2026.
How has Krystal Biotech, Inc.'s total liabilities & equity changed year-over-year?
Krystal Biotech, Inc.'s total liabilities & equity increased by 30.0% year-over-year, from $1.07B to $1.4B.
What is the long-term trend for Krystal Biotech, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Krystal Biotech, Inc.'s total liabilities & equity has grown at a 33.8% compound annual growth rate (CAGR), from $310.84M to $1.33B.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Krystal Biotech, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude